Delivering therapies to the brain remains a major challenge due to the limited permeability of the blood-brain barrier. In a ...
Low-grade brain tumors known as IDH-mutant gliomas CNS WHO grade 2 are life-threatening in spite of their slow growth.
As part of the presentation Dr. Silberman will discuss the Company's drug candidate, TPI 287. TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) ...
Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...